Every Wednesday at 8:30we're joined by John Perreault, Executive Director of theBerkshire Humane Societyto discuss all the happenings at their Barker Road facility, plus talk about their Pet of the Week.

This week's Pet of the Week is Pantera, a beautiful black domestic shorthair cat who is approximately8 years old. This friendly boy was found as a stray in Pittsfield so shelter staff does not have any information about his background. Pantera is an affectionate cat and will be your best buddy, but hes just not fond of other cats. He's great around children and dogs, just not other cats.

As a pet more than 7 years old, he qualifies for a senior discount a bargain because he probably has many more years to live and love! If you are interested in Pantera, please call Berkshire Humane Society's feline department at 413-447-7878, extension 124.

TheBerkshire Humane Society is now back open to the public for regular hours.

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

Why do they meow? Why do they nap so much? Why do they have whiskers? Cats, and their undeniably adorable babies known as kittens, are mysterious creatures. Their larger relatives, after all, are some of the most mystical and lethal animals on the planet. Many questions related to domestic felines, however, have perfectly logical answers. Heres a look at some of the most common questions related to kittens and cats, and the answers cat lovers are looking for.

The rest is here:
Berkshire Humane Society Pet of the Week: Meet Pantera - Live 95.9

Every 4th of July we receive reminders not to have pets (cats and dogs) join us for fireworks displays because of their sensitive hearing. This prompted me to research what animal has the best hearing in the world.

The answer is an insect. Yes, all insects are animals.

The average human hearing ranges between 20 Hz and 20 kHz and we have three muscles that assist us in completing the hearing process. This list is from a few different websites including bioexplorer.netand hearinghealthusa.

The top ten are listed below

This is very fascinating information but my question is can they identify each sound? For example can they discern a jackhammer from a crying baby? Or is it just a noise to them?

If you are interested in cats you might want to check this out.

Why do they meow? Why do they nap so much? Why do they have whiskers? Cats, and their undeniably adorable babies known as kittens, are mysterious creatures. Their larger relatives, after all, are some of the most mystical and lethal animals on the planet. Many questions related to domestic felines, however, have perfectly logical answers. Heres a look at some of the most common questions related to kittens and cats, and the answers cat lovers are looking for.

If you are a dog enthusiast here is some information for you.

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

See more here:
Hearing Champion of the World is An Insect - kdhlradio.com - kdhlradio.com

A week of life in Hoboken + Jersey City means there is plenty of news to catch up on. Among the local headlines the summer food program has been announced, Mission50 has opened following a rebranding, cases of COVID-19 remain low in Hoboken, and so much more. Keep reading for all the news you missed this week in Hoboken, Jersey City, + beyond.

Jersey City Medical Center opened a new center that expands the services the hospital is able to provide for comprehensive cancer care this month, according to RWJ Barnabas. This new infusion center provides community residents with convenient and unparalleled access to outstanding cancer care, right here in Jersey City, Michael Prilutsky, president and CEO of JCMC said in a statement. We would like to thank the Madeline Fiadini LoRe Foundation for the vision and generosity that made this Infusion Center possible.

The coffee culture in Jersey City is alive and well and ever-growing. The newest cafe to open in Chilltown is a popular Bayonne-based shop, Perk Up Cafe that is be located at 197 Van Voorst Street. The cafe is known for specialty coffees and espresso as well as a menu inspired by American classics and is aiming to open towards the end of July or the beginning of August. Click here to readmore about Perk Up Cafes new location in Jersey City and what to expect.

Photo credit: Google Maps

Following a fire in the 1930s the Windsor Wax building was still operational for a number of decades, reported Patch. Now, the City of Hoboken is proposing the building serve a new purpose as a redeveloped mixed-use site which would include 60 residential units. The building is located on Newark Avenue in Hoboken.

Another pet daycare, Camp Bow Bow has opened in Hoboken as of June 25th and hopes to take care of your little furry one when youre unable to. Click here to readwhat we know about Camp Bow Wow located at 1414 Grand Street in Hoboken.

Since its inception in 2020, the rideshare program Via has taken off, per NJ.com. As demand continues to rise local officials have approved an expansion of the current fleet. More than 340,000 rides have been completed so far. In the fifth quarter alone nearly 124,000 rides were completed which has also increased wait times. The additional vehicles will hopefully curb that delay.

In the wake of the pandemic, Governor Murphy signed a bill that will provide a temporary one-year extension of special education and related services to students with disabilities, reported Tap Into. Students who currently or will in the future exceed the current age of eligibility for special education and related services will qualify for additional services to help bring them up to speed.

Jersey City firefighter, Theron Jenkins, used downtime during the COVID-19 pandemic to work out. Eventually, he competed in the OCB competition in May in Atlantic City and won first place in the novice category, per NJ.com.

I only did this so I can learn how to lose weight and be happy and comfortable when I go to the pool, look at myself in pictures, and when I put my clothes on each day, said Jenkins. Those things are first place to me, thats the real win, not the trophy.

Litzky Public Relations, the Hoboken-based boutique agency, hasannounced anall-newgrant program calledLOVE. Litzky will provide a grant of $25,000 to support businesses that work to better the lives of children and families. LPR has proudly chosen PunkinFutz, a NY-based company creating sensory play products for kids that make play accessible for every child, as the first recipient of the LOVE, Litzky Grant Program for 2021.

Ar Movies Under the Stars this week, a 16-minute documentary was played before the feature film was produced entirely during the lockdown in Hoboken. The Mile in the Eye is a short story of how Hoboken, the fourth-most densely populated city in the country, less than a mile from NYC, the ground zero of the pandemic outbreak, overcame the incredible challenge and was called a model for the rest of the country. Click here to view the trailer.

Twin Boro Physical Therapy has recently merged with Hoboken-based Craft Physical Therapy. The practice is located at 1422 Grand Street. The new merged practice will open on Monday, June 28th. The owners of Craft PT, Caroline Jolly and Sandy Pietrewitz are longtime Hoboken residents.

After opening its first location at 527 Monroe Street in Hoboken in the summer of 2020, Cafe Vista garnered much-deserved attention for itsgood quality coffee, tea, and pastries, as well as its unique design and Instagram worthy vibes. Now, a year later, the cafe is set to open its second location in Jersey City next month. Click here to read more about Cafe Vistas new Jersey City location at 177 York Street.

The Trustees of theHoboken Public Library announced on June 23rd the boards months-long search for a new library director has come to a conclusion. The search for a new director began early this year when Library Director Lina Podles announced her retirement effective June 1st.

The Trustees engaged Bradbury-Miller Associates, an executive search consultant specializing in helping libraries find leaders who are an excellent fit. After what turned out to be a nationwide search, four finalists were identified the trustees voted unanimously to appoint Jennie Pu, currently the Dean of College Libraries at Hudson County Community College, to be the new leader of Hobokens public library. Click here to read the full story.

The Hoboken Food Pantry recently announced that the fundraiser held in May resulted in $11,330 in raised funds. With this money, we can continue our mission to fight food insecurity in and around Hoboken as well as helping families secure other basic items. Thank you so much to our incredible donors and a special shoutout to Dr. Kansky at Eyeshapes Hoboken for matching all donations up to $5,500! We have such an incredible community and are continually blown away by the amount of support we have received, the announcement said.

Photo credit: @sosflkeys

To ensure all Jersey City Youth have access to free, healthy meals during summer break, Mayor Fulop and the Jersey City Department of Health and Human Services announced this years Summer Food Service Program, according to Insider NJ. This program will provide free, healthy meals to children ages 18 and under, using 52 sites citywide to serve 225,000 meals. This program is federally funded, state-administered and run locally by Jersey Citys HHS, running from June 28th to August 27th.

Photo credit: @mvmk.architecture

Jersey City has approved a new 172-unit complex, and the development scheme can officially move forward, per Jersey Digs. The properties that are planning on revitalizing are owned by Hoboken-based company 199 Summit LLC. The new building will include 86 residential units, 89 parking spaces, 1,045 square feet of retail space, and a roof deck for residents.

On Thursday, June 24th Mission50 celebrated its official reopening with a ribbon-cutting ceremony. Formerly the Hoboken Business Center (HBC), Mission 50 is a reimagined 80,000-square-foot boutique office building and coworking community that responds to evolving workplace needs and fosters collaboration, creativity, and productivity. Mission50 is located at 50 Harrison Street in Hoboken.

Members of the Order of the Knights of Rizal laid a wreath in honor of Jose Rizals 160th birthday on June 19th, per Tap Into. They laid this wreath at the statue of Rizal located in the park at Christopher Colombus Drive and Brunswick. Rizal was executed by the Spanish colonial government in the Philippines in 1896.

Jersey City is planning to add nearly 50-speed bumps across the city, starting June 28,according to NJ.com. Mayor Fulop announced this change in a recent Facebook post, telling residents to reach out to their city council representative to request a speed bump on their street.

After taking a year off due to the COVID-19 pandemic, New Jerseys Freedom andFireworks event is back and better than ever. This year, the City of Jersey City will be working with the Jersey Night Market, a woman- and Latinx-owned small business, to bring some fun to the waterfront festivities. Click here to read more about Jersey Citys July 4th grand celebration.

SW3AT Sauna, the popularsauna studio located in downtown Jersey City at 172 Newark Avenue, has expanded to the Mile Square. SW3AT is a veteran-, woman-, LGBTQ+-, and black-owned holistic sanctuary for those seeking to heal the mind and body with infrared heat therapy and with limited sauna studios available in Hoboken, were pretty excited! Click here to read moreabout SW3AT Saunas new Hoboken location at 89 Hudson Street.

Newark Avenue closures are still in place near the Hudson County Courthouse, per Patch. Water utility work is continuing, as a result, the closure and detour of the westbound travel lane of Newark Avenue between Baldwin Avenue and Central Avenue will continue. The path will reopen once the utility work is finished.

On Tuesday, June 22nd Doctors Lyons and Ferrucci celebrated the opening of the new Regenerate Soft Wave Therapy office in Hoboken with an official ribbon-cutting ceremony. This SoftWave Therapy practice is the first and only clinicin Northern New Jersey to offer this highly effective treatment to reduce pain. Regenerate SoftWave Therapy is an FDA-cleared, alternative to surgery and a non-invasive, drug-free treatment for inflammation, chronic pain, diabetes, and all joint issues.

This is a game-changer for patients everywhere, Dr. Ferrucci told Hoboken Girl. Softwave Therapy regenerates orthopedic injuries by immediately decreasing inflammation, improving blood flow, and activating stem cells to aid in the healing process. We are thrilled to see how many patients of all ages now come to our Hoboken clinic, and we are seeing first-time patients feel immediate results.

Thyson T. Halley, a lifelong Jersey City resident, realized the introduction of masks in a learning environment brings obstacles to those with hearing impairments,according to Tap Into. To combat this, he teamed up with the citys Department of Health and Human Service to distribute see-through masks. He distributed masks to staff and others at Zambella School which he designated for deaf students.

Hoboken has opened eight new locations to drop off composting, raising the number from four to 12. The expansion is part of Hobokens Climate Action Plan, seeking to reduce greenhouse gas emissions. Composting is a simple and effective way to help Hoboken achieve its goals for the Climate Action Plan. Click here to read what we know.

RoofTop at Exchange Place announced via Instagram it has opened reservations for July 4th. With one of the best views of the Hudson River, tickets start at $150. The post reads, This is what you have been waiting for! Celebrate the Fourth of July with us on the Rooftop or Terrace with fireworks views and great drinks!

The free Movie Under the Stars event in Hoboken on Wednesday night will feature the Elton John biopic Rocket Man, but will also screen a 16-minute documentary about how Hoboken handled COVID-19, per Patch. The film will include scenes with TV Cake Boss Buddy Valastro as well as medical professionals. The documentary is titled The Mile In The Eye.

A 100 percent plant-based eatery will be opening at 464 Newark Street in Hoboken soon. With a location already operating in Newark, Vegbar Juicerys owners Mel Vaughn and Binta Forrest shared with Hoboken Girl how the Hudson County location will be different. Click here for more details about Vegbar Plant-Based Kitchen and Juice Bar in Hoboken and what to expect.

Hoboken has announced that it is opening enrollment for summer youth programs, according to Tap Into. These programs include baseball, basketball, and gymnastics. Registration opened on Tuesday, June 22nd.

A good massage in Hoboken, while not impossible to find, can be tricky depending on your needs. Deep tissue, relaxing, coupled with cupping/CBD there are many things that you can add to a massage, but often it leaves you wanting more. But when it comes to a true craftsman in the massage world, allow us to introduce Dominic Concepcion. Dominic is newer to the Hoboken massage scene but lets just say, hes got healing hands, and he just started working at EC Beauty Studio in Hoboken at 80 River Street 2x/week. Click here to read more.

Vitos Deli, a popular Hoboken restaurant, and Court Street, an eatery on the citys old cobblestone path have both been awarded the This Place Matters designation, per Patch. The Hoboken Historical Preservation Commission has been awarding this designation for two years, starting with the oldest businesses and moving on to some newer Hoboken destinations.

Castaway Vintage announced this week via Instagram, it will be hosting a pop-up shop in downtown Jersey City this week. The post said, Hey yall!! Backyard pop-up shoppe. Dont miss it!! It will be fun. Lite refreshments. DWTN Jersey City. The Villages. Look for signs. Wednesday, June 30th; Thursday, July 1st; and Friday, July 2nd. The store sells a fun mix of home goods, candles, and gifts.

For the past 30 days, not a single Hoboken resident was hospitalized with COVID-19 at the Hoboken University Medical Center, according to Hudson Reporter. During the pandemics peak, HUMC cared for 124 COVID-19 patients in one day. As of June 18th, 97 percent of Hoboken residents ages 65 and up; 65 percent of residents over 18; and 58 percent of all residents of any age had gotten at least one dose of the COVID-19 vaccine.

Hoboken is home to many a four-legged friend and every year The City of Hoboken hosts a free rabies vaccination clinic. This year on June 26th, per Tap Into, the dogs of Hoboken gathered for their free shot. The clinic operated from 11AM to 2PM at the multi-service center. The clinic will run from 11AM to 2PM at the Multi-Service Center.

The Department of Health Building scheduled to be built this year will be named after Health Commissioner Judy Persichilli, according to Tap Into. The Judith M. Persichilli building will recognize her service during the COVID-19 pandemic.

Gov. Phil Murphy and state legislative leaders agreed to add free tuition for certain students and tax breaks for seniors to the 2022 budget, per Patch. This would provide two years of free tuition at New Jersey universities for students from households making less than $65,000 per year. Murphys administration expects the program to benefit tens of thousands of New Jersey students.

In an Instagram post this week SNL set designer and local dog trainer, Ken MacLeod announced, Starting this summer we will be Introducing Puppy Club! Puppy Club is the perfect opportunity for pups to practice their skills. Under the supervision of a certified trained professional, owners with dogs under 4 months can ask questions in-person & learn about their own dogs play style and personality while playing safely with other city pups. Puppy Clubs are limited to 6 puppies. Dates to be announced soon!

The Hoboken thrift store, St. Mary Advocates Inc. announced this week via Instagram it will now accept payment via credit card and Apple Pay. This update will make it easier for the local community to support Hoboken Thrift in its mission as customers no longer need to worry about carrying cash.

Studio 17 Cosmetics & Wellness has reopened, which means aging gracefully is once again, an easy option. Clients go to Dr. Briza Walter for her effective non-invasive, anti-aging procedures. Studio 17 is located at 601 9th Street in Hoboken. Click here to read more about this local spot.

On Wednesday, June 30th the Jersey City Council will meet to vote on Ordinance 21-041 which, if passed, would change single-stall bathrooms across Jersey City to gender-neutral bathrooms. The community is invited to speak at the meeting click here to sign up.

Frank Rongo should have graduated from what was then called AJ Demarest High School in Hoboken in 1951, but following his fathers death, he dropped out of school and started working to support his family, reported News 12 . Never graduating high school. Now 70 years later, he has been awarded an honorary high school diploma from Hoboken High School.

Rongos grandson said, Every year for the last 29 years, my grandpa here was telling me how much he regretted having to leave high school. He served his country, he worked hard his whole life. He just never had the opportunity to go back and finish it.

Originally from North Carolina, Ainsley became a proud Hoboken Girl years ago. As a freelance journalist she has written about everything under the sun for the past six years. She works from her home office in uptown Hoboken or sometimes from Choc-o-Pain, because nothing says freelancer like working from a caf with a fresh croissant nearby. As the mother of one very fast toddler, she has a passion for self-care, parenting hacks, and discovering all the fun things the Mile Square has to offer.

View post:
39 Hoboken + Jersey City News Stories You Missed This Week - hobokengirl.com

If you recall, back in 2019,The Illinois Environmental Protection Agency (IEPA) and the Illinois Department of Public Health (IDPH)were asking Illinois residents to be more vigilant about where they boat, ski, and swimover the summer due to blue-green algae "blooms" thatwere occurring in Illinois' lakes and rivers.

Blue-green algae, also known ascyanobacteria,is back at it once again in Illinois' lakes and rivers, and the Illinois Environmental Protection Agency (IEPA) says that the warm temperatures we've been experiencing not only in the Rockford area but statewide, are causing new blooms of this stuff.

Most of the blue-green algae blooms, according to the IEPA,are harmless, but...

"...some can producetoxic chemicals that cause sickness or other health effects in people and pets, depending on theamount and type of exposure.Sensitive individuals, including young children, the elderly, and people with compromisedimmune systems are most at risk to adverse health effects attributable to algal toxins. Symptoms of exposure to algal toxins includerashes, hives, diarrhea, vomiting, coughing, or wheezing."

Whenever we get blue-green algae blooms in Illinois, local officials are supposed to report it and put up signage warning of its presence in local waterways, but as you might imagine, that doesn't always happen.

If you should find yourself near a body of water that doesn't feature warnings around it, the IEPA says you should look for the following signs of a blue-green algae bloom:

Not that any of us are in the habit of letting our dogs run headlong into scummy-looking bodies of water, but sometimes they'll get away from us. If your dog is exposed to (or may have been) blue-green algae, don't let them lick their fur (or any other parts) until you can get them cleaned off with clean, fresh water. Then, contact your veterinarian.

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

See the original post:
Deadly Algae That Can Kill Your Dog Is Growing In Illinois Lakes - 1440wrok.com

Baseball is a methodic game. Patience prevails, even when you are attacking a 98 mph fastball. However, in a society where fast food is too slow, the interest in baseball, especially for the younger audiences is dwindling at an alarming rate. Between 2009 - 2019 tickets sold for major league baseball games declined by 10 million per year. Going to a big league game has become an all day affair and if you go at night, you wont get out until 10pm at the earliest, too late for many kids...the future consumers.

The MLB Commissioner is getting hammered by the players, media and the fans. He, along with the owners he works for, have lost touch with what made this sport great. Video replay challenges, guys stepping out of the box, pitchers taking almost a full minute between pitches and pitcher inspections have, in Miami Marlins manager, Don Mattinglys words, made the game unwatchable. But no one in the Commissioners office listens.

I dont like it but 7 inning games are a good start. As is a time clock to make the pitcher throw the ball to the plate in a more timely manner. Making the batter stay in the batter's box and be ready is another thing. The game needs to be complete in two and a half hours. Three and four hour games are painful, no matter what team wins.

Now Commissioner Manfred has added another slow down mechanism, the pitcher inspection for the sticky stuff that he is blaming on the lack of offense in the Major Leagues. Well, the sticky stuff has been around longer than the lack of offense problem. The lack of hits and run production problem can be traced to Manfred himself, who decided to deaden the baseball. I guess young fans dont like home runs.

As long as Rob Manfred is the Commissioner of Major League Baseball, we can continue to watch the sport that so many love continue to fade away.

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

See the original post here:
The Slow Death of America's Pastime - WTMM 104.5 The Team - ESPN Radio

Cannabidiol (CBD) and tetrahydrocannabinol (THC) are fairly hot-button topics in veterinary medicine that are difficult to unpack, with no distinguishable gray areaor so I thought. Historically, I always seem to encounter either the die-hard holistic believers or their antipode, the gold standard Western medicine practitioners. However, in recent years I have learned there are many closet supporters of CBD who find it difficult to openly endorse as a legitimate treatment modality because of either lack of clinical understanding or fear of legal ramifications.

As a CBD user who has experienced quantifiable results, I firmly believe there is a place for CBD in veterinary medicine that does not have to be limited to holistic practices. After all, anyone working in emergency medicine is likely familiar with Yunnan Baiyao, a traditional Chinese medicine used in hemorrhagic cases for its presumed hemostatic qualities. All that being said, this is my attempt at addressing the CBD debate.

To understand when and why CBD is appropriate to discuss or use in veterinary medicine, we must first understand what it is. This requires a general understanding of the cannabis plant. CBD and THC are phytocannabinoid derivatives of the cannabis species.1 Cannabis is an umbrella term for any hemp or marijuana plant with a THC concentration that has not been quantified; marijuana is cannabis with a determined THC concentration greater than 0.3%; and hemp is cannabis or any part of the plant with a determined THC concentration less than 0.3%.2 The Cannabaceae family can be broken down into the species Cannabis sativa and subspecies Cannabis indica and Cannabis ruderalis.2

Although the cannabis community has created a perception that one species is known for higher concentrations of THC over CBD and vice versa, concentrations of either can vary by species and the chemical makeup is greatly affected by how the particular strain is grown. In actuality, the differences between the species largely come down to where the plant originated and the general appearance (eg, plant size and leaf shape).3

As mentioned, CBD is a phytocannabinoid, which acts on the endocannabinoid system (ECS). The ECS exists within humans and animals, vertebrates and invertebrates alike, and regulates functions in nearly every organ system throughout the body. It consists of G protein-coupled cell-membrane receptors and endogenous cannabinoid ligands, commonly referred to as endocannabinoids.2 The receptors most important in understanding the use of cannabis in medicine are cannabinoid receptors 1 and 2 (CB1R and CB2R). CB1R is found mainly within the central and peripheral nervous systems with some general distribution throughout the body, whereas CB2R is found mainly within the immune system.4

Canines specifically have been found to have a greatly increased number of CB1R within the cerebellum and brain stem compared with humans, which due to the preferential binding of THC to these receptors accounts for the pronounced clinical signs that we see with marijuana toxicosis.5 CBD interacts with receptors quite differently than THC does.

CBD has a weak affinity for receptors but can cause some antagonist activity at CB1R and inverse agonist activity at CB2R.4 In humans, this inverse agonist activity has been shown to reduce some of the psychoactive adverse effects (AEs) of THC when used in conjunction with CBD, and is known as the entourage effect.5 In veterinary medicine, THC is not a treatment option, but that does not mean CBD cannot be.

We know what CBD does on a chemical level, but what is important is the quantifiable response to consistent use. The FDA has only approved 1 cannabis-derived CBD product for use in human medicine. Epidiolex is used to control seizure episodes associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.6 In clinical trials, it showed an average reduction of seizure activity across the 3 syndromes by 39% to 48% over 14- to 16-week periods.6 Outside of prescription use, CBD users tout it for its benefits in controlling pain, appetite and nausea, anxiety and depression, and insomnia, just to name a few. I personally have experienced benefits in controlling chronic pain, anxiety, and shift work-related insomnia. With all of the clinical and anecdotal evidence available in human CBD use and the knowledge that animals have an endocannabinoid system akin to humans, it is fairly reasonable to assume that the benefits of use in veterinary medicine would be similar to those we experience. However, exploration of CBD in veterinary medicine did not gain popularity until very recently.

There have only been a handful of CBD studies in animals, with most of the focus on epilepsy and osteoarthritis. Two notable studies are those conducted by Colorado State University (CSU) and Cornell University. The study conducted by CSU involved the use of CBD to treat canine epilepsy. Although it was a small-scale study, the results were promising with 90% of participants experiencing a decrease in seizure activity7 and a median reduction in seizure activity of 33%.8

The Cornell study addressed canine osteoarthritis and results showed a reduction of pain and improved mobility in over 80% of the participants, suggesting CBD to be an appropriate adjunct therapy in the treatment and management of osteoarthritis.9 In both these studies, minimal AEs were noted with the most significant being an increase in serum alkaline phosphatase.9,10

A safety study conducted by Canopy Animal Health also indicated that CBD oil is well tolerated in canines, with over 94% of AEs scored as mild and mainly involving gastrointestinal signs and elevated serum alkaline phosphatase.10 Unfortunately, there is limited study data available on the safety and efficacy of CBD use in felines.

As proven in multiple studies, CBD can be an effective, safe therapy for many animals, which begs the question of why more veterinarians are not recommending it. Until very recently, CBD was classified as a Schedule I drug under the Controlled Substances Act (CSA) and therefore federally illegal. The passing of the Agricultural Improvement Act of 2018, known popularly as the 2018 farm bill, removed hemp and hemp-derived products from the definition of marijuana, thereby declassifying it as a scheduled substance under the CSA so long as the plant and products contain less than 0.3% THC.11 However, the hemp bill preserved the United States Food and Drug Administrations right to regulate any cannabis and cannabis derivatives under the Food, Drug, and Cosmetic Act,11 meaning veterinarians cannot legally prescribe CBD as a treatment protocol and must use diligence when discussing its use with clients.

Additionally, although CBD is now legal at the federal level, there are still 8 states with restrictions regarding sales and use,12 which adds another layer of complexity when considering its use in veterinary medicine. The only way to safely discuss CBD with a client is to refrain from stating that it is a drug that can treat or cure any particular illness. As with any other unregulated supplement or nutraceutical, the loophole exists wherein we can discuss how it can support a particular bodily system or function.

As part of my own research, I recently polled peers, veterinarians, technicians, and assistants to learn their opinions regarding CBD. I asked 2 questions: Do you believe CBD has a future in veterinary medicine, and why or why not? The responses were overwhelmingly in favor of CBD, feeling that it cant hurt and might help. Some of my peers already use CBD for their own animals mostly for its anxiolytic effects and to support mobility and appetite; a few had experience with successful use in epileptic cases in animals whose seizures were poorly managed with multiple anticonvulsant medications. One person had no opinion in either direction due to lack of experience with it. One was firmly against its use, citing a study suggesting no legitimate benefit in patients with epilepsy and concern about misuse at the hands of owners.

Despite the opinions that CBD does have a future, the support comes with stipulations. The primary concern is that there needs to be appropriate training provided to veterinary professionals and equivalent education to owners to prevent misuse; for example, an owner intentionally using a product containing THC, causing a toxicity case. Having seen a large increase in marijuana ingestion cases following the legalization of recreational use in my state, I tend to agree that the risk increases without proper education. The other concerns surround the potential for owners to put all their hope on CBD as a replacement for Western medicine, the fear of legal repercussions for veterinarians, and the stark lack of supporting clinical evidence, and the risk that clients, in an effort to cut costs, will use products from companies that cannot provide Independent Lab Testing for proof of quality, purity, and potency.

Considering all the current information on CBD use in human medicine, the beginnings of research in veterinary medicine, and the changes in legality, I strongly believe it has a future in our field. I did not previously subscribe to the hype and I would refuse to discuss the topic with clients or owners who were seeking support and approval for their decisions to experiment with CBD. But like the field, I have evolved and transitioned from my previously adamant no to a willingness to discuss without making recommendations. Now, I can safely say I am ready to openly advocate for its use if it can improve the quality of life for our patients.

I have found that most clients interested in the properties of CBD are pursuing it as a last-ditch effort, frequently as an adjunct therapy in hospice care or to mitigate the AEs of chemotherapy treatment. These owners have nothing left to lose but their animal companions. They, as well as all pet owners, deserve the opportunity to discuss other options. We exist in this profession for the betterment of our patients and their owners; we have an obligation to seek new and better therapies and right now that means we need to focus more attention on CBD research. For me, there is no debate. I am Team CBD all the way.

Janelle Overholser, CVT, is an ICU veterinary technician for BluePearl Specialty and Emergency Pet Hospital. She is a graduate of Penn Foster College and recently returned to school to obtain her BAS degree in veterinary technology. She is passionate about emergency medicine and is pursuing her VTS in ECC.

References

Continue reading here:
When and why: The CBD debate - DVM 360

We all know that dogs have been forever called mans best friendand throughout the pandemic dog adoptions increased because more people wanted to have acompanion during lockdowns. In our area there were several pets adopted and there is a new service that will help you train your newfour-leggedfriend.

Purpose Pups LLC in Houlton is now open and hosting a grand opening this Saturday June 12from noon until 5:00 pm.The family-owned business specializes in full-servicedog training and several Elite Dog Trainings solutions. Tyler Jonesis the trainer for Purpose Pups which is owned by his parents David and Helen Jones. David is a retired Navy veteran and Helen has been achildren'sdisabilityadvocate for over 40 years.

Meet Tyler Jones:

Whats behind the name?

Purpose Pups name is not incidental. P.U.R.P.O.S.E.ProvideUsefulReliablePartnershipsOurSocietyEmploys. If youve ever adopted a pet for general purposes or for therapeutic reasons then you know that the intention behind the name is spot on.

But theres got to be more to the story?

Yes,there is more to the story of Purpose Pups and how the business came into realization.It's a great story of redemption and a reminder that even when you get knocked down in life theres always a chance to get back up and keep fighting. Tylercame up with the idea for Purpose Pups while in the NEADS(National Education for Assistance Dog Services)Prison Pup program.After being sentenced to 9 years for a nonviolent marijuana crimeTyler was able to receive excess of 7,000 hours of positivereinforcement-basedtraining.

Take on Tyler's attitude

At a time in life when many people would give up or continue on the same journey, Tyler made the choice to better himself. He hit the ground running with his vision of Purpose Pups. As you cansee,he is well versed in dog traininghad has his animal trainer certifications from the Department of Labor.

Purpose Pups can train your dog for obedience training, loose leash walking andcommand response.In my opinion, the most valuable service Tyler offers our area isService Dog Training. This is a huge need in Aroostook County right now and with adoptions on the rise there is a need for thisspecification.Tyler can work with service dogs, emotional support dogs, therapy dogs, and much more.

For more information stop by Purpose Pups at 70 Bangor Street in Houlton or follow Purpose Pups LLC Facebook page.A complete list of servicesareavailable at the Purpose Pups website

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

See more here:
Incredible Story And Purpose Behind New Houlton Business - q961.com

Walking out of my home at 4am to 72 degree, humid weather was a stark reminder that summer is pretty much here. Yes, the official start of summer is on June 20th, but with 90 degree days I'm sure we're all ready to get out and enjoy the sun.

However, if you're a dog owner there are a few things to look out for to make sure your pup stays safe during the hotter months.

The SPCA of SW Michigan recently shared a Facebook post outlining what to look out for and how to avoid summertime issues with your pet.

First, let's start with the 'top tips'...they may be common knowledge but it's always nice to have a reminder:

There are a few things you should always avoid when it comes to your dog and the summertime heat:

Now, with the introduction of newer, smarter cars you may be able to leave the car parked and running with the air conditioning going. However, there are still far too many cases of people leaving their animals in a parked, locked, hot car because they'll 'only be in the store for a minute'.

Earlier in my life I worked as a receptionist at a veterinarian's office in Florida. We only saw one dog for heat stroke but it was because they left this poor baby in the car. They had only been in the store for 10, maybe 15 minutes but that was all it took. Cars become much hotter much faster than any of us realize.

We can do our best to plan and prepare but what happens to a dog when they're overheated or experiencing a heat stroke? Here's what to look out for:

Those are among the few signs and symptoms to look out for. See the full list here.

As well, there are specific breeds that are more susceptible to heat stroke. If you have any of the following breeds, or dogs that fall under these categories, make sure to monitor them closely:

If you're anything like me the instinct to rescue an animal in a dangerous situation is...strong. However, laws regarding breaking windows to save a dog from overheating vary from state to state. Brush up on Michigan's laws, which prohibit you from breaking that window, below:

With the majority of cats residing indoors, the SPCA says you don't usually have to worry about them overheating in normal circumstances. After all, they never leave the house. If, however, you have an outdoor cat the SPCAsays that you can always provide a little outdoor shelter to offer a bit of shade.

To prepare yourself for a potential incident, always keep your vet's phone number handy, along with an after-hours clinic you can call in an emergency. The ASPCA Animal Poison Control Center also has a hotline you can call at (888) 426-4435 for advice.

Even with all of these resources, however, the best cure for food poisoning is preventing it in the first place. To give you an idea of what human foods can be dangerous, Stacker has put together a slideshow of 30 common foods to avoid. Take a look to see if there are any that surprise you.

LOOK: The least obedient dog breeds

Visit link:
Keep Your Dog Safe This Summer: Tips from the SPCA of SW Michigan - wkfr.com

Like all the other verticals, the healthcare vertical is poised to witness an amalgamation of collaborations and networks as a result of the culture of belonging and inclusion being the new DNA therein. Also, remote work arrangements will be simplified with shared services, cloud technologies, and AI is in place. The Canine Stem Cell Therapy Market is meant to capture these happenings and give insights regarding the same.

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade.

Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Get Sample Copy of Report @https://www.persistencemarketresearch.com/samples/15550

Company Profiles

Get To Know Methodology of Report @https://www.persistencemarketresearch.com/methodology/15550

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field.

The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness aCAGR of 4.2%during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation ofUS$ 218.2 Mnby the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs.

A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment.

However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Access Full Report @https://www.persistencemarketresearch.com/checkout/15550

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians.

A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

About Us:

Persistence Market Research is here to provide companies a one-stop solution with regards to bettering customer experience. It does engage in gathering appropriate feedback after getting through personalized customer interactions for adding value to customers experience by acting as the missing link between customer relationships and business outcomes. The best possible returns are assured therein.

Contact Us:

Persistence Market ResearchAddress 305 Broadway, 7th Floor, New York City, NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Salessales@persistencemarketresearch.comWebsite https://www.persistencemarketresearch.com

See more here:
The Canine Stem Cell Therapy Market To Witness An Exponential Satiation In The Next 10 Years The Courier - The Courier

8 of 11 Patients in Dose Escalation Cohorts 2 and 3 Achieved Objective Response

6 of 11 Patients Achieved Complete Response, including 2 Patients Previously Treated with Autologous CD19 CAR T-cell Therapy

Favorable FT516 Safety Profile Was Observed; No FT516-related Serious Adverse Events or FT516-related Grade 3 or Greater Adverse Events

Outpatient Treatment Regimen Was Well-tolerated; No Events of Any Grade of Cytokine Release Syndrome, Immune Effector Cell-Associated Neurotoxicity Syndrome, or Graft-vs-Host Disease

SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today highlighted positive interim Phase 1 data from the Companys FT516 program for patients with relapsed / refractory B-cell lymphoma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually June 4-8, 2021. FT516 is the Companys universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor, which is designed to maximize antibody-dependent cellular cytotoxicity (ADCC), a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells. The ongoing Phase 1 dose-escalation study of FT516 is currently enrolling patients in the fourth dose cohort of 900 million cells per dose.

As of the data cutoff date of March 11, 2021, four patients in the second dose cohort of 90 million cells per dose and seven patients in the third dose cohort of 300 million cells per dose were evaluable for assessment of safety and efficacy. Eight of eleven patients achieved an objective response, including six patients who achieved a complete response, as assessed by PET-CT scan per Lugano 2014 criteria (see Table 1). Patients had received a median of three prior lines of therapy and a median of two prior lines containing CD20-targeted therapy. Of the eleven patients, eight patients had aggressive B-cell lymphoma, five patients were refractory to their most recent prior therapy, and four patients were previously treated with autologous CD19 CAR-T cell therapy.

These additional data from our Phase 1 study of FT516 administered off-the-shelf in the outpatient setting continue to reinforce its differentiated safety profile and underscore its potential clinical benefit, said Wayne Chu, M.D., Senior Vice President of Clinical Development of Fate Therapeutics. Based on the favorable therapeutic profile of FT516 that continues to emerge and the potential to treat patients on-demand without delay, we plan to initiate multiple indication-specific, dose-expansion cohorts for patients with B-cell lymphomas to broadly assess FT516 in combination with CD20-targeted monoclonal antibody regimens, including those used as standard-of-care in earlier-line settings.

The ongoing Phase 1 clinical trial in relapsed / refractory B-cell lymphoma is assessing FT516 in an off-the-shelf treatment regimen of up to two cycles, with each cycle consisting of three days of conditioning chemotherapy (500 mg/m2 of cyclophosphamide and 30 mg/m2 of fludarabine), a single-dose of rituximab (375 mg/m2), and three weekly doses of FT516 each with IL-2 cytokine support. The FT516 treatment regimen is designed to be administered in the outpatient setting.

Safety DataNo dose-limiting toxicities, and no FT516-related serious adverse events or FT516-related Grade 3 or greater adverse events, were observed. The FT516 treatment regimen was well tolerated, and no treatment-emergent adverse events (TEAEs) of any grade of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease were reported by investigators (see Table 2). All Grade 3 or greater TEAEs were consistent with lympho-conditioning chemotherapy and underlying disease. Of note, a Grade 3 or greater TEAE of infection was reported in one patient only. There were no discontinuations due to adverse events, and no patients withdrew from the study except in the setting of disease progression. In addition, no evidence of anti-product T- or B-cell mediated host-versus-product alloreactivity was detected, supporting the potential to safely administer up to six doses of FT516 in the outpatient setting without the need for patient matching.

Activity DataAs of the data cutoff date of March 11, 2021, eleven relapsed / refractory patients in the second and third dose cohorts were evaluable for assessment of safety and efficacy. Of the eleven patients, nine patients completed both FT516 treatment cycles and eight patients achieved an objective response, including six patients who achieved a complete response, as assessed by PET-CT scan per Lugano 2014 criteria. Notably, two of four patients previously treated with autologous CD19 CAR-T cell therapy achieved a complete response. Two patients showed progressive disease following the first FT516 treatment cycle and discontinued treatment. The Company previously reported that two patients treated in the first dose cohort (30 million cells per dose) showed progressive disease.

Patient Case StudyThe ASCO presentation featured a case study of a 36-year old male with triple-hit, high-grade B-cell lymphoma with rearrangements of MYC, BCL2, and BCL6 genes. The patient was refractory to all prior lines of therapy with the exception of autologous CD19 CAR T-cell therapy, for which a complete response of two months duration was achieved. The patient was most recently refractory to an investigational CD20-targeted T-cell engager and presented with bulky lymphadenopathy with the largest lesion measuring approximately 10 centimeters. The first FT516 treatment cycle resulted in a complete response with resolution of all metabolically active disease and 85% reduction in the size of target lesions. Subsequent to the data cutoff date of March 11, 2021, the patient completed a second FT516 treatment cycle after which the response assessment continued to show complete response.

As of March 11, 2021 database entry. Data subject to source document verification.CR = Complete Response; PR = Partial Response; PD = Progressive DiseaseCAR = Chimeric antigen receptor; DH/DE = Double-hit / double expressor; DLBCL = Diffuse large B-cell lymphoma; FL = Follicular lymphoma; Gr = Grade; HGBCL = High-grade B-cell lymphoma; iNHL = Indolent non-Hodgkin lymphoma; TH = Triple-hit; Transformed iNHL = Aggressive B-cell lymphoma transformed from indolent non-Hodgkin lymphoma1 Cycle 2 Day 29 protocol-defined response assessment per Lugano 2014 criteria2 Subject did not proceed to Cycle 23 Confirmed DLBCL (transformation from Gr3A FL) subsequent to the data cutoff date of March 11, 20214 Cycle 2 Day 29 protocol-defined response assessment reported subsequent to the data cutoff date of March 11, 2021

CRS = Cytokine Release Syndrome; DL = Dose Level; GvHD = Graft vs. Host Disease; ICANS = Immune Cell-Associated Neurotoxicity Syndrome;M = Million; SAE = Serious Adverse Event; TEAE = Treatment-Emergent Adverse Event1 Includes two subjects in the first dose cohort of 30 million cells per dose

About Fate Therapeutics iPSC Product PlatformThe Companys proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that are designed to be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Companys first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Companys platform is uniquely designed to overcome numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 350 issued patents and 150 pending patent applications.

About FT516FT516 is an investigational, universal, off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line engineered to express a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor, which has been modified to prevent its down-regulation and to enhance its binding to tumor-targeting antibodies. CD16 mediates antibody-dependent cellular cytotoxicity (ADCC), a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells. ADCC is dependent on NK cells maintaining stable and effective expression of CD16, which has been shown to undergo considerable down-regulation in cancer patients. In addition, CD16 occurs in two variants, 158V or 158F, that elicit high or low binding affinity, respectively, to the Fc domain of IgG1 antibodies. Scientists from the Company have shown in a peer-reviewed publication (Blood. 2020;135(6):399-410) that hnCD16 iPSC-derived NK cells, compared to peripheral blood NK cells, elicit a more durable anti-tumor response and extend survival in combination with anti-CD20 monoclonal antibodies in an in vivo xenograft mouse model of human lymphoma. Numerous clinical studies with FDA-approved tumor-targeting antibodies, including rituximab, trastuzumab and cetuximab, have demonstrated that patients homozygous for the 158V variant, which is present in only about 15% of patients, have improved clinical outcomes. FT516 is being investigated in a multi-dose Phase 1 clinical trial as a monotherapy for the treatment of acute myeloid leukemia and in combination with CD20-targeted monoclonal antibodies for the treatment of advanced B-cell lymphoma (NCT04023071). Additionally, FT516 is being investigated in a multi-dose Phase 1 clinical trial in combination with avelumab for the treatment of advanced solid tumor resistant to anti-PDL1 checkpoint inhibitor therapy (NCT04551885).

About Fate Therapeutics, Inc.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Companys immuno-oncology pipeline includes off-the-shelf, iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens using chimeric antigen receptors (CARs). Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.fatetherapeutics.com.

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the safety and therapeutic potential of the Companys iPSC-derived NK cell product candidates, including FT516, its ongoing and planned clinical studies, and the expected clinical development plans for FT516. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that results observed in studies of its product candidates, including preclinical studies and clinical trials of any of its product candidates, will not be observed in ongoing or future studies involving these product candidates, the risk that the Company may cease or delay clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials, the amount and type of data to be generated, or otherwise to support regulatory approval, difficulties or delays in subject enrollment and continuation in current and planned clinical trials, difficulties in manufacturing or supplying the Companys product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development), and the risk that its product candidates may not produce therapeutic benefits or may cause other unanticipated adverse effects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Companys actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Companys periodic filings with the Securities and Exchange Commission, including but not limited to the Companys most recently filed periodic report, and from time to time in the Companys press releases and other investor communications.Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact:Christina TartagliaStern Investor Relations, Inc.212.362.1200christina@sternir.com

Read this article:
Fate Therapeutics Highlights Positive Interim Data from its Phase 1 Study of FT516 in Combination with - GlobeNewswire